Alopecia-intellectual disability syndrome 2

Summary

Alopecia-intellectual disability syndrome 2 (MONDO:0012487) is a disease. A subtype of alopecia - intellectual disability syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	alopecia-intellectual disability syndrome 2
Mondo ID	MONDO:0012487
MeSH	C563668
OMIM	610422
DOID	DOID:0080629
UMLS	C1835852
MedGen	372142
GARD	0004291
Is cancer (heuristic)	no

Also known as: alopecia intellectual disability syndrome 2 · alopecia with mild to moderate intellectual deficit · alopecia-intellectual disability syndrome 2 · alopecia-mental retardation syndrome 2 · AMR syndrome 2 · APMR2

Disease family

This is a subtype of alopecia - intellectual disability syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › alopecia - intellectual disability syndrome › alopecia-intellectual disability syndrome 2

Related subtypes (3): alopecia-intellectual disability syndrome 3, alopecia-intellectual disability syndrome 1, alopecia-intellectual disability syndrome 4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.